title: [Chemotherapy and immunotherapy of metastatic malignant melanomas].
abstract: Prognosis in metastatic malignant melanoma is poor because of chemo and radiotherapy resistance. However, some drugs, such as dacarbazine, cisplatinum or fotemustine, a new nitrosourea, have produced a response rate of more than 20%. Combining these drugs increases response rate to 30-40%. Immunotherapy by interferon-alpha 2 shows about 15-20% response rate but interleukin-2 would be more effective especially in combination with cisplatinum and interferon-alpha 2 with 50% response and long survival after cessation of treatment.
authors.affiliation: SOMPS, Hôpital de la Salpêtrière, Paris.
authors.forename: A
authors.initials: A
authors.lastname: Benhammouda
authors.forename: G
authors.initials: G
authors.lastname: Auclerc
authors.forename: D
authors.initials: D
authors.lastname: Coeffic
authors.forename: M
authors.initials: M
authors.lastname: Weil
authors.forename: D
authors.initials: D
authors.lastname: Nizri
authors.forename: C
authors.initials: C
authors.lastname: Soubrane
authors.forename: P
authors.initials: P
authors.lastname: Banzet
authors.forename: D
authors.initials: D
authors.lastname: Khayat
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary / Q000628:therapy*
vernacular_title: Chimiothérapie et immunothérapie des mélanomes malins métastatiques.